Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Acta Cir Bras ; 39: e395329, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39109783

RESUMO

PURPOSE: To evaluate the neuroprotective effect of resveratrol, urapidil, and a combined administration of these drugs against middle cerebral artery occlusion (MCAO) induced ischemia/reperfusion (IR) injury model in rats. METHODS: Thirty-five rats were divided into five groups of seven animals each. Animals in IR, IR resveratrol (IRr), IR urapidil (IRu), and IR + combination of resveratrol and urapidil (IRc) were exposed to MCAO induced cerebral ischemia reperfusion injury model. Rats in IRr and IRu groups received 30-mg/kg resveratrol and 5-mg/kg urapidil respectively. Animals in IRc received a combined treatment of both drugs. At the end of the study, brain tissues were used for oxidative stress (malondialdehyde, glutathione, and superoxide dismutase), pro-apoptotic caspase-3, anti-apoptotic Bcl-2, and pro-inflammatory tumor necrosis factor-α cytokine level measurements. RESULTS: The MCAO model successfully replicated IR injury with significant histopathological changes, elevated tissue oxidative stress, and upregulated apoptotic and inflammatory protein expression in IR group compared to control group (p < 0.001). All parameters were significantly alleviated in IRr group compared to IR group (all p < 0.05). In IRu group, all parameters except for caspase-3 and Bcl-2 were also significantly different than IR group (all p < 0.05). The IRc group showed the biggest difference compared to IR group in all parameters (all p < 0.001). The IRc had higher superoxide dismutase and Bcl-2 levels, and lower caspase-3 levels compared to both IRr and IRu groups (all p < 0.05). Also, the IRc group had lower MDA and TNF-α levels compared to IRu group (all p < 0.05). CONCLUSIONS: The results indicate that combined treatment of resveratrol and urapidil may be a novel strategy to downregulate neurodegeneration in cerebral IR injury.


Assuntos
Modelos Animais de Doenças , Fármacos Neuroprotetores , Estresse Oxidativo , Traumatismo por Reperfusão , Resveratrol , Estilbenos , Animais , Resveratrol/farmacologia , Resveratrol/uso terapêutico , Traumatismo por Reperfusão/tratamento farmacológico , Traumatismo por Reperfusão/prevenção & controle , Fármacos Neuroprotetores/uso terapêutico , Fármacos Neuroprotetores/farmacologia , Masculino , Estresse Oxidativo/efeitos dos fármacos , Estilbenos/uso terapêutico , Estilbenos/farmacologia , Quimioterapia Combinada , Ratos Wistar , Infarto da Artéria Cerebral Média/tratamento farmacológico , Resultado do Tratamento , Ratos , Fator de Necrose Tumoral alfa/análise , Superóxido Dismutase/análise , Superóxido Dismutase/metabolismo , Malondialdeído/análise , Malondialdeído/metabolismo , Reprodutibilidade dos Testes , Apoptose/efeitos dos fármacos , Distribuição Aleatória , Isquemia Encefálica/tratamento farmacológico , Antioxidantes/uso terapêutico , Antioxidantes/farmacologia , Caspase 3/metabolismo , Caspase 3/análise
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA